专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008157003A2 CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS 审中-公开
标题翻译： BFL-1化学抑制剂及相关方法
公开(公告)号：WO2008157003A2
公开(公告)日：2008-12-24
申请号：PCT/US2008/065422
申请日：2008-05-30
申请人： THE BURNHAM INSTITUTE , REED, John, C. , ZHAI, Dayong , KITADA, Shinichi , SERGIENKO, Eduard
发明人： REED, John, C. , ZHAI, Dayong , KITADA, Shinichi , SERGIENKO, Eduard
IPC分类号： A61K31/5377 , A61K31/496 , G01N33/53 , A61P35/00
CPC分类号： A61K31/496 , A61K31/5377 , G01N2500/02
摘要： Compounds that bind to BfI-1 as well as conjugates of such compounds are provided. Various embodiments additionally provide methods of using such compounds to identify additional anti-apoptotic BfI- 1 binding compounds. Methods of using such compounds to increase apoptosis in a cell are also provided.
摘要翻译：提供了结合BfI-1的化合物以及这些化合物的缀合物。各种实施方案另外提供使用这些化合物鉴定另外的抗凋亡BfI-1结合化合物的方法。还提供了使用这些化合物增加细胞凋亡的方法。

2. 发明申请

WO2008154207A9 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS 审中-公开
公开(公告)号：WO2008154207A9
公开(公告)日：2008-12-18
申请号：PCT/US2008/065567
申请日：2008-06-02
申请人： THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH , REED, John, C. , YIP, Kenneth , SERGIENKO, Eduard , SU, Ying
发明人： REED, John, C. , YIP, Kenneth , SERGIENKO, Eduard , SU, Ying
IPC分类号： G01N33/53 , G01N33/00
摘要： An assay for determining compounds that inhibit activity of a BC1-2 protein, or affect conversion of Bc1-2 from an antiapoptotic to a proapoptotic form are described. In addition, compounds that modulate the function of anti-apoptotic proteins such as Bc1-2 and related Bc1-2 family members are identified.

3. 发明申请

WO2007092899A2 INHIBITORS OF MEMBRANE TYPE-1 MATRIX METALLOPROTEINASE FOR THE TREATMENT OF INSULIN-DEPENDENT DIABETES MELLITUS 审中-公开
标题翻译：用于治疗胰岛素依赖性糖尿病的膜类型1基质金属蛋白酶的抑制剂
公开(公告)号：WO2007092899A2
公开(公告)日：2007-08-16
申请号：PCT/US2007/061796
申请日：2007-02-07
申请人： THE BURNHAM INSTITUTE , STRONGIN, Alex, Y. , SAVINOV, Alexei, Y. , ROZANOV, Dmitri, V.
发明人： STRONGIN, Alex, Y. , SAVINOV, Alexei, Y. , ROZANOV, Dmitri, V.
CPC分类号： A61K38/57 , A61K31/19
摘要： Provided herein are compositions and methods for inhibiting the transmigration of T cells through pancreatic capillary endothelium and treating insulin-dependent diabetes mellitus (IDDM; type I diabetes) using inhibitors of MTl-MMP.
摘要翻译：本文提供了通过胰腺毛细血管内皮抑制T细胞迁移并使用MT1-MMP抑制剂治疗胰岛素依赖性糖尿病（IDDM; I型糖尿病）的组合物和方法。

4. 发明申请

WO2007090194A2 LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS 审中-公开
标题翻译：肿瘤中的淋巴管编码和预防恶性肿瘤
公开(公告)号：WO2007090194A2
公开(公告)日：2007-08-09
申请号：PCT/US2007/061480
申请日：2007-02-01
申请人： THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , RUOSLAHTI, Erkki , ZHANG, Lianglin , HANAHAN, Douglas
发明人： RUOSLAHTI, Erkki , ZHANG, Lianglin , HANAHAN, Douglas
IPC分类号： C07K7/08
CPC分类号： C07K7/06 , A61K38/00 , A61K47/48353 , A61K47/665 , B82Y5/00 , C07K5/1019 , C07K7/08 , C07K2319/01 , C07K2319/10 , C07K2319/20 , G01N33/5088 , G01N33/574 , G01N33/57415 , G01N33/57434 , G01N2500/00
摘要： Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
摘要翻译：本文公开了选择性靶向肿瘤淋巴管的组合物和方法。

5. 发明申请

WO2006102068A3 METHODS AND COMPOSITIONS FOR DEREPRESSION OF IAP-INHIBITED CASPASE 审中-公开
公开(公告)号：WO2006102068A3
公开(公告)日：2006-09-28
申请号：PCT/US2006/009695
申请日：2006-03-17
申请人： THE BURNHAM INSTITUTE , TORREY PINES INSTITUTE FOR MOLECULAR STUDIES , REED, John, C. , HOUGHTEN, Rihcard, A. , NEFZI, Adel , OSTRESH, John, M. , PINILLA, Clemencia , WELSH, Kate
发明人： REED, John, C. , HOUGHTEN, Rihcard, A. , NEFZI, Adel , OSTRESH, John, M. , PINILLA, Clemencia , WELSH, Kate
IPC分类号： A01N37/18
摘要： The invention provides isolated agents having novel chemical structures and possessing superior activity as derepressors of IAP inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase. The invention further provides assay methods employing labeled compounds of the invention, especially fluorescent labeled compounds.

6. 发明申请

WO2005081904A2 ANTIMICROBIAL CARBOHYDRATES AND METHODS OF USING SAME 审中-公开
标题翻译：抗微生物碳水化合物及其使用方法
公开(公告)号：WO2005081904A2
公开(公告)日：2005-09-09
申请号：PCT/US2005/005407
申请日：2005-02-18
申请人： THE BURNHAM INSTITUTE , SHINSHU UNIVERSITY , NAKAYAMA, Jun , KAWAKUBO, Masatomo , FUKUDA, Minoru , KATSUYAMA, Tsutomu
发明人： NAKAYAMA, Jun , KAWAKUBO, Masatomo , FUKUDA, Minoru , KATSUYAMA, Tsutomu
IPC分类号： A23L33/00
CPC分类号： C07H1/00 , C07H5/04 , C07H5/06 , C07H9/00 , C07K14/70596 , C12P21/005
摘要： Compositions useful for inhibiting the growth of bacteria, including bacteria that can cause gastric ulcers, are provided. In addition, transgenic organism that can produce such compositions are provided. Methods of using the compositions to treat or prevent gastric ulcers in a subject, including a human subject, also are provided.
摘要翻译：提供了可用于抑制细菌生长的组合物，包括可引起胃溃疡的细菌。此外，提供了可以生产这种组合物的转基因生物体。还提供了使用该组合物治疗或预防受试者（包括人类受试者）胃溃疡的方法。

7. 发明申请

WO2005065354A2 DEFINED MEDIA FOR PLURIPOTENT STEM CELL CULTURE 审中-公开
标题翻译：定义的细胞培养基
公开(公告)号：WO2005065354A2
公开(公告)日：2005-07-21
申请号：PCT/US2004/043858
申请日：2004-12-31
申请人： THE BURNHAM INSTITUTE , PARSONS, Xuejun, Huang , SNYDER, Evan, Y.
发明人： PARSONS, Xuejun, Huang , SNYDER, Evan, Y.
IPC分类号： A01N63/00 , A61K35/12 , C12N5/00 , C12N5/02 , C12N5/0735 , C12N5/074 , C12N5/10 , G01N33/50
CPC分类号： C12N5/0606 , A61K35/12 , C12N5/0607 , C12N2500/38 , C12N2500/44 , C12N2500/90 , C12N2500/98 , C12N2501/115 , C12N2501/33 , C12N2502/13 , C12N2503/00 , C12N2533/52 , C12N2533/54 , G01N33/5073
摘要： Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium free conditions remain crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation. Having discerned these minimal molecular requirements, conditions that would permit the substitution of poorly-characterized and unspecified biological additives and Substrates were derived and optimized with entirely defined constituents, providing a “biologics”-free( i.e. , animal-, feeder-, serum-, and conditioned-medium-free) system for the efficient long-term cultivation of pPSCs, particularly pluripotent hESCs. Such culture systems allow the derivation and large-scale production of stem cells such as pPSCs, particularly pluripotent hESCs, in optimal yet well-defined biologics-free culture conditions from which they can be efficiently directed towards a lineage-specific differentiated fate in vitro , and thus are important, for instance, in connection with clinical applications based on stem cell therapy and in drug discovery processes.
摘要翻译：干细胞，包括哺乳动物，特别是灵长类动物原始干细胞（pPSCs）如人类胚胎干细胞（hESCs），对恢复细胞，组织和器官功能具有重要的前景。然而，干细胞，特别是未分化的hESCs的培养在无血清，无饲养细胞和无条件培养基的条件下对于用于基于细胞的疗法的多能细胞的大规模，均匀生产以及用于控制条件以有效地指导其谱系特异性分化。本发明基于发现维持pPSC，特别是未分化hESC的长期生长所必需的最小必需成分的配方。碱性成纤维细胞生长因子（bFGF），胰岛素，抗坏血酸和层粘连蛋白被认为既足够又是必需的，以维持hESCs处于能够延长繁殖，然后进行定向分化的健康自我更新未分化状态。鉴于这些最小的分子要求，可以使用完全限定的成分衍生和优化允许代表不良表征和未指定的生物添加剂和底物的条件，提供“生物制剂”（即动物，饲料，血清 - ，无条件培养基）系统，用于高效长期培养pPSCs，特别是多能性hESC。这样的培养系统允许干细胞的衍生和大规模生产，例如pPSC，特别是多能hESC，在最佳且明确定义的不含生物制剂的培养条件中，从而可以有效地将其引导到体外特有的分化命运，因此例如与基于干细胞治疗和药物发现过程的临床应用相关是重要的。

8. 发明申请

WO2005041882A2 MOLECULES THAT SELECTIVELY HOME TO VASCULATURE OF PREMALIGNANT OR MALIGNANT LESIONS OF THE PANCREAS AND OTHER ORGANS 审中-公开
标题翻译：选择性地选择胰腺和其他器官的恶性肿瘤或恶性损伤的分子
公开(公告)号：WO2005041882A2
公开(公告)日：2005-05-12
申请号：PCT/US2004/036047
申请日：2004-10-29
申请人： THE BURNHAM INSTITUTE , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , HANAHAN, Douglas , RUOSLAHTI, Erkki
发明人： HANAHAN, Douglas , RUOSLAHTI, Erkki
IPC分类号： A61K
CPC分类号： C07K14/4748 , A61K38/00 , A61K47/62 , A61K49/0043 , A61K49/0056 , C07K7/06
摘要： The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
摘要翻译：本发明提供了一种缀合物，其包括连接至肽或肽模拟物的治疗部分，所述肽或肽模拟物选择性地居住于恶化前胰腺的脉管系统。肽或模拟肽含有选自CRSRKG（SEQ ID NO：9）和CEYQLDVE（SEQ ID NO：34）的氨基酸序列的至少5个连续氨基酸，或其保守性变体或肽模拟物。本发明另外提供了包含与肽或肽模拟物连接的治疗性部分的缀合物，所述肽或肽模拟物选择性地归巢至胰腺肿瘤细胞和胰腺肿瘤脉管系统，所述肽或拟肽包含选自CKAAKNK（SEQ ID NO：1）的氨基酸序列的至少5个连续氨基酸，SEQ ID NO：15），CKGAKAR（SEQ ID NO：19）和VGVGEWSV（SEQ ID NO：35），或其保守变体或肽模拟物。

9. 发明申请

WO2004022710A2 METHODS OF MODULATING CELL DEATH BASED ON THE BIT1/AES REGULATORY PATHWAY 审中-公开
标题翻译：基于BIT1 / AES法规路径调节细胞死亡的方法
公开(公告)号：WO2004022710A2
公开(公告)日：2004-03-18
申请号：PCT/US2003/027710
申请日：2003-09-05
申请人： THE BURNHAM INSTITUTE , JAN, Yiwen , MATTER, Michelle , PAI, Jih-Tung , RUOSLAHTI, Erkki
发明人： JAN, Yiwen , MATTER, Michelle , PAI, Jih-Tung , RUOSLAHTI, Erkki
IPC分类号： C12N
CPC分类号： C07K14/4747 , C07K14/4703 , C07K14/4705
摘要： The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent.
摘要翻译：本发明提供了鉴定改变Bit1多肽与AES多肽的缔合的有效试剂的方法。该方法通过使Bit1多肽或其活性片段和AES多肽或其活性片段与允许Bit1多肽或其活性片段与AES多肽或其活性片段缔合的条件与试剂接触来实施; 并检测Bit1多肽或其活性片段和AES多肽或其活性片段的改变的关联，其中改变的缔合表明该试剂是改变Bit1多肽与AES多肽的缔合的有效试剂。这种有效的药剂可以调节细胞凋亡并且可以是有用的治疗剂。

10. 发明申请

WO2003088975A1 INHIBITION OF FATTY ACID SYNTHASE BY BETA-LACTONES AND OTHER COMPOUNDS FOR INHIBITION OF CELLULAR PROLIFERATION 审中-公开
标题翻译：通过BETA-LACTONES和其他化合物抑制脂肪酸合成抑制细胞增殖的抑制作用
公开(公告)号：WO2003088975A1
公开(公告)日：2003-10-30
申请号：PCT/US2003/011420
申请日：2003-04-11
申请人： THE BURNHAM INSTITUTE
发明人： SMITH, Jeffrey, W. , AXELROD, Fumiko , KRIDEL, Steven, J.
IPC分类号： A61K31/585
CPC分类号： A61K31/337 , A61K31/335 , A61K31/336 , A61K31/365 , A61K31/40 , A61K31/42 , A61K31/425 , A61K31/445 , A61K31/585 , G01N33/5011 , G01N2333/91057
摘要： The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis.
摘要翻译：本发明的特征在于通过向受试者施用有效量的β-内酯来治疗受试者的癌症的方法。本发明还具有通过向受试者施用有效量的脂肪酸合酶抑制剂来抑制受试者血管生成的方法。这些方法可用于治疗各种癌症和其他疾病和病症。本发明还涉及鉴定可用于本发明治疗肿瘤，抑制血管发生以及涉及病理性血管生成的疾病和病症的治疗的β-内酯和其它化合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式